Emails between a Schering-Plough executive and the principle investigator of the ENHANCE trial were made public today by Sen. Chuck Grassley. The emails reveal that the ENHANCE trial’s principal investigator perceived that the drugmakers were withholding unfavorable results about ezetimibe/simvastatin (Vytorin) for non-scientific reasons. (Surprise Surprise). Instead of releasing the bad data, Sen. Grassley noted, Merck/Schering-Plough went on a marketing blitz to increase Vytorin prescriptions.ÂÂ